Searching... Searching...
  • NVP + NA
  • Köp NA
  • Sälj NA
  • Senast NA
  • SEK

  • Buy NA
  • Sell NA
  • Latest NA
  • USD

Company presentations

Abliva‘s objective is to design pharmaceuticals that preserve the integrity and function of mitochondria for indications where there is a great unmet medical need. Abliva is continuously engaged in the vibrant mitochondrial science community as well as the world of investors and potential partners. 

Aktiespararna’s Kvinnokvällen, 12 October 2020, Gothenburg, Sweden

Redeye’s Orphan drugs, 27 May 2020

CEO presentation at the Annual General Meeting 2020

Lund, Sweden, on 20 May 2020.

Redeye Digital Investor Forum, 31 March, 2020.

Erik Penser Bank Bolagsdag, 12 March, 2020, Stockholm, Sweden.

Stockholm Corporate Finance 12th Life Science seminar, 11 March, 2020.

Aktiespararna’s Aktiedagen Lund, 28 January 2020, Lund, Sweden.

Aktiespararna’s Stora Aktiedagen, 25 November 2019, Stockholm, Sweden.

Redeye Life Science Day, 19 November 2019, Stockholm, Sweden

BioStock Life Science Summit, 23 October 2019, Lund, Sweden.

NeuroVive Capital Markets Day, 9 October, 2019, Stockholm, Sweden.

Mitochondria Day, 18 September 2019, Stockholm, Sweden

Stockholm Corporate Finance 11th Life Science seminar, 13 – 14 March 2019.

Aktiedagen Lund 2019, 29 January


Comments are closed.

IR Contact

Catharina Johansson


+46 (0) 46-275 62 21

  • Press Releases

    Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures 08 October Abliva AB (Nasdaq Stockholm: ABLI) today announces that M... Read More